|

I Tried 5-MeO-DMT at a Psychedelic Retreat. This is MY Story

BySarah Abelsohn



Have you ever considered taking 5-MeO-DMT, also known as Bufo Alvarius? If so, this video is for you.

Swati Sharma, Media Director of PsychedelicSpotlight.com sits down with James Hallifax to discuss her recent psychedelic experience.

She traveled to Tepotzlan, Mexico to partake in a psychedelic ceremony, where participants took the psychedelic substance. Was she healed by psychedelics? Did psychedelics help her mental health? What was the experience like?

Tune in to find out more!

Don’t forget to like and subscribe!

source

Similar Posts

  • How Long Until Psychedelic Stocks Payoff?🍄🚀| MindMed (MNMD), Cybin (CYBN), Numinus (NUMI) and more

    Listen, Videos

    How long until Psychedelic Stocks Payoff?🍄🚀

    To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/

    Follow us on Twitter:
    @Psy_Invest
    @psy_holy
    @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    While researching a possible investment into psychedelic stocks, you have almost certainly heard the refrain of, “It’s a long-term investment.” I myself, in my many videos for The Psychedelic Investor and articles for PsychedelicSpotlight.com, have probably said this over 100 times.

    And while the thesis for investing in psychedelic stocks is appealing, having a timeline clearer than “it’s a long term investment” is necessary before deciding whether it is worth the risk.

    In this video, therefore, I endeavor to answer a big question: “When will psychedelic stocks provide a significant return on investment?”

    Or, translated to Reddit-speak: when moon?

    To start, I feel it’s necessary to give the warning that the answer may be never. To be clear, while I personally believe in the potential for psychedelic stocks such as MindMed (Nasdaq: MNMD, NEO: MMED) and Cybin (NYSE: CYBN, NEO: CYBN), the entire psychedelic medicines industry is inherently speculative and there is no guarantee of success. Yes, the science right now suggests that treatments such as MDMA therapy for PTSD and Ketamine therapy for addiction will disrupt the mental healthcare market, but this needs to be confirmed in larger studies.

    There will be two separate turning points for psychedelic medicines and the companies that produce them: the legalization of the first psychedelic medicines, and the legalization of improved next-generation psychedelics.

    The first will happen relatively soon.

    #PsychedelicStocks #MindMed #Cybin

  • Mendeleyev: Music, Magic, Mushrooms

    Listen

    In the realm where music meets the mystical, few artists embody the fusion of psychedelic exploration and sonic innovation like Mendeleyev.

  • LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]

    Listen, Videos

    Hey Psychedelic Investors, today we are actually going to have two episodes, one to present the news updates, and then a second one, which will take place in the Speculation Zone to discuss why these may be super important
    So make sure you stick around for both.

    Timecodes:
    0:00 – Intro
    3:30 – New Phase 1 Clinical Trial
    9:45 – Changes in Leadership
    13:19 – New MindMed Partnership
    20:30 – Conclusion

    So what is the latest MindMed news and what does it mean for the future of MMED/MMEDF?

    First up, we have news from the end of January that MindMed has started their phase one clinical trial combining MDMA with LSD.

    Why combine these two substances?
    What diseases could it help alleviate?
    And what is the timeline for this project?

    Next we will cover MindMed’s change in leadership structure. A CEO has stepped down, does this mean we are seeing a game of thrones in the boardroom? Well… no. It’s actually much more practical than that.

    Here we will cover: Why did they do this, and how will it affect MMED/MMEDF going forward, specifically with MindMed ‘s Nasdaq Uplisting application.

    Finally, and most importantly, we will talk about how MindMed is further expanding their development pipeline and IP portfolio through a partnership with a Swiss company called MindShift Compounds. This is very exciting as it ads to MindMed’s ever expanding clinical trial pipeline.

    Pretty soon it’s going to be hard keeping track of all of MindMed’s projects.

    Hey there guys so before we begin the episode I just want to let you know that I was just interviewed on the channel The Medicine of being Human.
    We talked about all sorts of interesting topics and I had a great time.

    I am not sure if by the time this video is released, if the interview will already be out, but ill put a link in the description to the Channel, and also to Sena’s Instagram page.
    https://www.youtube.com/channel/UChW422KBFaEfB9DJG_cKySQ
    https://www.instagram.com/sena__maria/

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor

    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video from Pexels

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMEDF #MindmedStock